Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 402-408

  Matsunaga, Toshiyuki ^a   Yamane, Yumi ^a   Iida, Keiko ^a   Endo, Satoshi ^a   Banno, Yoshiko ^b   El Kabbani, Ossama ^c   Hara, Akira ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MONASH UNIVERSITY   (Australia)

Author keywords

4 hydroxy 2 nonenal; aldo keto reductase 1B10; colon cancer cells; drug resistance; mitomycin c

Indexed keywords

4 HYDROXYNONENAL; MITOMYCIN C; OXIDOREDUCTASE; PROTEIN AKR1B10; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIPID PEROXIDATION; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; ALDEHYDES; ANTIBIOTICS, ANTINEOPLASTIC; CASPASE 3; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; LIPID PEROXIDATION; MITOMYCIN; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 79955051623     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283448df0     Document Type: Article

References (44)

1. Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT. Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie 2008; 31:271-281. (Pubitemid 351744829)
2. Iyer VN, Szybalski W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci USA 1963; 50:355-362.
3. Lee YJ, Park SJ, Ciccone SL, Kim CR, Lee SH. An in vivo analysis of MMCinduced DNA damage and its repair. Carcinogenesis 2006; 27:446-453. (Pubitemid 43378895)
4. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC. Role of NADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984; 44:5638-5643. (Pubitemid 15183570)
5. Park IC, Park MJ, Hwang CS, Rhee CH,Whang DY, Jang JJ, et al. Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett 2000; 158:125-132.
6. Kim R, Emi M, Matsuura K, Tanabe K. Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma. Gan To Kagaku Ryoho 2005; 32:1540-1545.
7. Hejna M, Wö hrer S, Schmidinger M, Raderer M. Postoperative chemotherapy for gastric cancer. Oncologist 2006; 11:136-145. (Pubitemid 43261760)
8. Morrow CS, Cowan KH. Mechanisms and clinical significance of multidrug resistance. Oncology 1988; 2:55-63.
9. Penketh PG, Shyam K, Sartorelli AC. Mechanisms of resistance to alkylating agents in drug resistance. In: Hait WN, editor. Drug Resistance. Boston: Kluwer; 1996. pp. 65-81.
10. Baumann RP, Hodnick WF, Seow HA, Belcourt MF, Rockwell S, Sherman DH, et al. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 2001; 61:7770-7776. (Pubitemid 33049363)
11. Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol 1996; 50:728-735. (Pubitemid 26347691)
12. Joseph P, Jaiswal AK. A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C. Br J Cancer 2000; 82:1305-1311. (Pubitemid 30145350)
13. Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009; 19:477-488.
14. Chen J, Adikari M, Pallai R, Parekh HK, Simpkins H. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2008; 61:979-987. (Pubitemid 351423125)
15. Selga E, Noé V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 2008; 75:414-426. (Pubitemid 350298467)
16. Bacolod MD, Lin SM, Johnson SP, Bullock NS, Colvin M, Bigner DD, et al. The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008; 8:172-179. (Pubitemid 351666854)
17. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y,Watanabe A, Shibahara J, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005; 11:1776-1785. (Pubitemid 40471839)
18. Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007; 67:7431-7438. (Pubitemid 47206573)
19. Yoshitake H, Takahashi M, Ishikawa H, Nojima M, Iwanari H, Watanabe A, et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 2007; 17:1300-1306. (Pubitemid 350077355)
20. Breton J, Gage MC, Hay AW, Keen JN, Wild CP, Donnellan C, et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 2008; 7:1953-1962.
21. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 2010; 16:2518-2528.
22. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, Cao D. Aldo-keto reductase family 1B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 2007; 121:2301-2306. (Pubitemid 47585613)
23. Crosas B, Hyndman DJ, Gallego O, Martras S, Paré s X, Flynn TG, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003; 373:973-979. (Pubitemid 36981109)
24. Martin HJ, Maser E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem Biol Interact 2009; 178:145-150.
25. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009; 284:26742-26748.
26. Esterbauer H,Weger W. Action of aldehydes on normal and malignant ceils. III: synthesis of homologous 4-hydroxy-2-alkenals 2 [German] Monatsh Chem 1967; 98:1994-2000.
27. Usui S, Matsunaga T, Ukai S, Kiho T. Growth suppressing activity for endothelial cells induced from macrophages by carboxymethylated curdlan. Biosci Biotechnol Biochem 1997; 61:1924-1925. (Pubitemid 127471792)
28. Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, Kitade Y, et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys 2009; 487:1-9.
29. Shiraishi H, Matsuura K, Kume T, Hara A. Expression of mRNAs for dihydrodiol dehydrogenase isoforms in human tissues. Adv Exp Med Biol 1999; 463:539-544.
30. Iino T, Tabata M, Takikawa S, Sawada H, Shintaku H, Ishikura S, et al. Tetrahydrobiopterin is synthesized from 6-pyruvoyl-tetrahydropterin by the human aldo-keto reductase AKR1 family members. Arch Biochem Biophys 2003; 416:180-187. (Pubitemid 36957843)
31. Endo S, Matsunaga T, Kuragano T, Ohno S, Kitade Y, Tajima K, et al. Properties and tissue distribution of a novel aldo-keto reductase encoding in a rat gene (Akr1b10). Arch Biochem Biophys 2010; 503:230-237.
32. Matsunaga T, Kotamraju S, Kalivendi SV, Dhanasekaran A, Joseph J, Kalyanaraman B. Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem 2004; 279: 28614-28624. (Pubitemid 38900144)
33. Lin D, Lee HG, Liu Q, Perry G, Smith MA, Sayre LM. 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol 2005; 18:1219-1231. (Pubitemid 41170246)
34. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006; 52:601-623.
35. Endo S, Matsunaga T, Kuwata K, Zhao HT, El-Kabbani O, Kitade Y, et al. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. Bioorg Med Chem 2010; 18:2485-2490.
36. Yang XD, Tang DN, Wang J, Cao DL. Screening of the drug resistanceassociated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1). Ai Zheng 2003; 22:1289-1295.
37. MacLeod AK, McMahon M, Plummer SM, Higgins LG, Penning TM, Igarashi K, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009; 30:1571-1580.
38. De Vries HE,Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med 2008; 45:1375-1383.
39. Morimitsu Y, Nakagawa Y, Hayashi K, Fujii H, Kumagai T, Nakamura Y, et al. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. J Biol Chem 2002; 277:3456-3463. (Pubitemid 34953214)
40. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 2004; 378:373-382. (Pubitemid 38367228)
41. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278:33714-33723. (Pubitemid 37553204)
42. Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, et al. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther 2009; 8:1995-2006.
43. Lee JH, Naito M, Nakajima M, Tsuruo T. Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells. Cancer Chemother Pharmacol 1993; 33:215-220.
44. Doorn JA, Srivastava SK, Petersen DR. Aldose reductase catalyzes reduction of the lipid peroxidation product 4-oxonon-2-enal. Chem Res Toxicol 2003; 16:1418-1423. (Pubitemid 37474091)